Treating Patients with Complex Metabolic Conditions

Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) is a late-stage clinical biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena’s lead product candidate, ALLN-177, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders.

Year Invested: 2011
Location: Newton, Mass.

Recent News

November 7, 2018
Allena Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update

November 6, 2018
Allena Pharmaceuticals to Present at Upcoming Investor Conferences in November

October 25, 2018
Allena Pharmaceuticals to Present Data Characterizing Significant Unmet Need in Enteric Hyperoxaluria at ASN Kidney Week 2018

Read More News

Associated Team Members

Robert Tepper, M.D.